researchers off the grant treadmill
In the last decade, the NIH
has introduced four programs with nontraditional funding structures for
high-risk, high-impact projects. Now the National Cancer Institute
has followed suit and launched the Outstanding Investigator Award-a generous
seven-year award designed to ease the grant-writing burden for selected
AstraZeneca's acquisition of Almirall's respiratory assets should buy time until other compounds in the pharma's pipeline mature.
For MannKind to recoup its investment, Sanofi must make good on its bet that Afrezza can succeed where Pfizer's Exubera failed.
Neoantigenics is developing diagnostics and therapeutics against oocyte-specific antigens to kill cancer cells while sparing fertility.
GestVision's rapid urine-based test uses amyloid measures to detect preeclampsia in the point of care setting.
IPOs are rewarding Flagship for sticking to its focus on novel, early stage platform plays.
Denmark's Forward Pharma is readying a U.S. push with NASDAQ IPO and confrontation with Biogen Idec in MS.
Handicapping valuation of a potential IPO by cancer immunotherapy play. Plus: TVM says FAAH; Intercept; Rigel; Achillion; Basilea; Dendreon; Insmed et al.
Dezima Pharma B.V. (Naarden, the Netherlands) said TA-8995 (DEZ-001) alone or in combination with statin therapy met the primary endpoint vs. placebo in the 364-patient Phase IIb TULIP trial to treat dyslipidemia. The primary endpoint was...
The CDK4 inhibitor palbociclib might help overcome ibrutinib resistance in mantle cell lymphoma by restoring sensitivity to inhibitors of BTK or PI3K.
The National Cancer Institute has created a generous seven-year award designed to ease the grant-writing burden for 'outstanding investigators'. Now the institute needs to ensure that the program is not just easier riches for the top labs but instead makes a difference for up-and-coming researchers.
GSK executive Perry Nisen has joined Sanford-Burnham as CEO and plans to apply his industry know-how to accelerate drug development at the institute.
The mechanisms by which dysfunctional glial cells contribute to ALS have remained poorly defined. Now, Harvard University researchers have identified a therapeutic target-prostaglandin D2 receptor subtype DP1-and shown that reducing its expression can prolong survival in a mouse model of ALS.
Treating cardiac hypertrophy with MST2 inhibitors; improving the outcome of HSC transplants with RET agonists; preventing allergic asthma with Helicobacter pylori ggt and vacA; and more...
An Sigirr-deficient mouse model of Campylobacter jejuni infection; a CAR-specific invariant NK T cell therapy; integrated analysis of cancer cells to prioritize the study of cancer drivers; and more...